Cancer Chemotherapy and Pharmacology

, Volume 26, Issue 6, pp 449–452 | Cite as

Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity

  • Joanne E. Mortimer
  • Ian Anderson


Intensive therapy with 5-fluorouracil (FU) and leucovorin (LV) has proved to be effective in the treatment of advanced colorectal cancer. The toxicity of this regimen has not been systematically evaluated. In the present study, 52 patients with advanced colorectal and refractory cancers received sequential 2-month cycles of weekly FU and high-dose LV and were monitored for toxicity as well as response in 103 cycles. Of 24 evaluable patients with colorectal cancer, 1 complete and 9 partial responses were seen (42%); 4 of 10 patients who had been refractory to conventional FU treatment responded to the FU/LV regimen. One partial response was observed among six patients with gastric carcinoma, and three minor responses were seen in five women with refractory breast cancer. A total of 24 patients (46%) completed the first cycle on schedule, although 7 subjects required a reduction in the dose of FU. The majority of patients required treatment breaks because of toxicity. Gastrointestinal toxicity proved to be dose-limiting on this schedule, necessitating FU dose modification and treatment of both diarrhea in 15 subjects and acute abdominal pain in 7 cases. No patient required a further treatment delay of FU dose adjustment. Myelosuppression was an uncommon complication on this regimen. Cutaneous toxicity was also prominent in this series of patients, with the hand-foot syndrome developing in 14 cases (27%); 11 subjects who developed this complication were treated with pyridoxine (150 mg daily), and all experienced improvement in their symptoms within 1 week. Partial and complete responses were observed in 41% of evaluable patients with colorectal cancer and in one of six evaluable patients with gastric carcinoma. We conclude that FU and high-dose LV can safely be given on a weekly basis, although acute gastrointestinal and cutaneous toxicity are common.


Clin Oncol Leucovorin Princess Margaret Hospital Cutaneous Toxicity Leucovorin Calcium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arbuck SG, Douglass HO, Trave F, Milliron S, Baroni M, Nova H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and high dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5: 1150–1156PubMedGoogle Scholar
  2. 2.
    Budd GT, Fleming TR, Bukowski RM, McCracken JD, Rivkin SE, O’Bryan RM, Balcerzak SP, MacDonald JS (1987) 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group study. J Clin Oncol 5: 272–277PubMedGoogle Scholar
  3. 3.
    Di Costanzo R, Bartolucci R, Padalino D, Brugia M, Buzzi F (1988) High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. Cancer Invest 6: 133–138PubMedCrossRefGoogle Scholar
  4. 4.
    Erlichman C, Fine S, Wong A, Elhakim T (1988) a randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475PubMedGoogle Scholar
  5. 5.
    Evans RM, Laskin JD, Hakala MT (1981) Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288–3295PubMedGoogle Scholar
  6. 6.
    Grem JL, Shoemaker DD, Petrelli NJ, Douglass HO (1987) Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil. J Clin Oncol 5: 1704PubMedGoogle Scholar
  7. 7.
    Gyorgy P, Eckhardt RE (1939) Vitamin B6 and skin lesions in rat. Nature 144: 512CrossRefGoogle Scholar
  8. 8.
    Herrera-Ornelas L, Petrelli N, Trave F, Mittelman A, Plager J, Creaven PJ, Rustum TM (1986) Toxicity and pharmacokinetics of 5-fluorouracil and high dose leucovorin factor administered by continuous intravenous infusion for 5 days to patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 5: 39Google Scholar
  9. 9.
    Hines JD, Zakem MH, Adelstein DJ, Rustum YM (1988) Treatment of advanced stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study. J Clin Oncol 6: 142–146PubMedGoogle Scholar
  10. 10.
    Houghton JA, Maroda SJ, Phillips JO, Houghton PJ (1981) Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41: 144–149PubMedGoogle Scholar
  11. 11.
    Madjewicz S, Petrelli N, Rustum YM, Campbell J, Herrera L, Mittelman A, Perry A, Creaven PJ (1984) Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 44: 4667–4468Google Scholar
  12. 12.
    Molina R, Fabian C, Slavik M, Dahlberg S (1987) Reversal of palmar-plantar erythrodysesthesia by B6 without loss of response in colon cancer patients receiving 200 mg/m2/day continuous 5-FU. Proc Am Soc Clin Oncol 6: 90Google Scholar
  13. 13.
    Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ, Mittelman A (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559–1565PubMedGoogle Scholar
  14. 14.
    Petrelli N, Srablein D, Bruckner H, Mayer R, Douglass H (1988) A prospective randomized phase III trial of 5-fluorouracil versus 5 FU + high dose leucovorin in patients with metastatic colorectal adenocarcinoma: a report of the gastrointestinal study group. Proc Am Soc Clin Oncol 7: 94Google Scholar
  15. 15.
    Rustum YM, Madjewicz S, Campbell J, Zakrzewski S, Petrelli N, Herrera LO, Mittelman A, Creaven PJ (1984) Clinical biochemical pharmacology of 5-formyltetrahydrofolate in combination with 5-fluorouracil in patients with advanced colorectal carcinoma: correlation with clinical response. In: Advances in Cancer Chemotherapy. Proceedings of a symposium. The current status of 5-fluorouracil-leucovorin calcium combination, New York, March 17, 1984, pp 77–82Google Scholar
  16. 16.
    Trave F, Rustum YM, Petrelli NJ (1988) Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol 6: 1184–1191PubMedGoogle Scholar
  17. 17.
    Ullman B, Lee M, Martin DW, Santi DV (1978) Cytotoxicity of 5-fluoro-2′-deoxyuridine: requirement for reduced folate cofactor and antagonism by methotrexate. Proc Natl Acad Sci USA 75: 980–983PubMedCrossRefGoogle Scholar
  18. 18.
    Waxman S, Bruckner H (1982) The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and alpha-tocopherol. Eur J Cancer Clin Oncol 18: 685–692PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Joanne E. Mortimer
    • 1
  • Ian Anderson
    • 1
  1. 1.Division of Medical OncologyUniversity of WashingtonSeattleUSA

Personalised recommendations